Thus, manipulating CD8 T cell cross-priming by cDC1s, by employing strategies to increase the number of cDC1s and enhancing their capacity of cross-priming in tumors and tumor draining LNs, represents an exciting approach to enhance anti-tumor CD8 T cell immunity and improve the efficacy of current cancer immunotherapies including ICB and ACT (see reference 13 for an excellent recent review on DC-based cancer immunotherapy). Here, CD8A is linked to cancer.